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Background: The deposition of amyloid peptides is associated with Alzheimer’s disease (AD). These amyloid
peptides are derived from the amyloid protein precursor (APP). Silymarin, a standardized extract of milk thistle,
which is currently used in liver diseases, may be effective in the inhibition of amyloid formation. However, its
effect has not been assessed on APP expression.
Results: In this study, first, the effect of silymarin was examined on the passive avoidance learning in a rat model of
AD. This model was induced by the intracerebroventricular injection of Aβ peptide (Aβ1–42) in Wistar rats. Rats were
treated with 70 and 140 mg/kgof the extract, once a day, for 4 weeks. Memory function that was evaluated in a
shuttle-cage test, showed improvement upon administration of this extract. Brain amyloid plaques had also
decreased upon administration of the extract. Furthermore, APP gene expression was compared in treated and
untreated groups. The result showed that silymarin was able to suppress APP expression.
Conclusion: Our results are in accordance with the in vitro tests concerning the positive antiamyloidogenic
property of the main component of silymarin, namely silibinin. We suggest that the beneficial effect of sylimarin in
the AD model is related to its capacity to disaggregate amyloid plaques and to suppress APP expression.
Considering the limited side effects of silymarin, this compound could be of use in AD therapy.
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Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder which has been characterized by the existence
of extraneuronal aggregates of amyloid β (Aβ) peptide as
well as intraneuronal deposits of hyperphosphorylated tau
[1]. It is usually assumed that Aβ (abeta) aggregation in the
brain is the starting trigger of a pathological cascade which
ultimately leads to synaptic dysfunction and loss, neuronal
death, and eventually cognitive dysfunction [2]; the process
includes also oxidative stress and inflammatory response,
which play their roles in neuronal dysfunction [3,4]. It is
suggested that the reactive microglia and astrocytes that* Correspondence: yaghmaei_p@srbiau.ac.ir; aehabibi@sina.tums.ac.ir
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reproduction in any medium, provided the orsurround the Aβ plaques in the AD brain may release re-
active oxygen species and proinflammatory molecules [5].
Various isoforms of Aβ peptide with lengths varying
from 14 to 42 aminoacids have been characterized which
are derivated from “APP”, the amyloid precursor protein
(APP) [6,7]. However, it is generally accepted that the
main dominant forms of Aβ (40 and 42 aminoacids) are
the toxic species involved in AD pathophysiology, as for
example, it has been shown that the presence of Aβ 42
in cerebrospinal fluid could be a reliable predictor of AD
progression [8].
The intracerebroventricular administration of Aβ pep-
tide into rodent brain has been used as a mean to simulate
AD disease, since this injection could induce histological
and biochemical changes as well as oxidative damage and
inflammatory responses which result into memory defi-
cits [9,10]. With this animal model, in vivo studies could
be performed to test potential new candidates for AD
therapy.ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-
(hydroxy-methyl)-2,3-dihydrobenzo[b][1,4]doxin-6-yl]
chroman-4-one] is the main compound of the herb milk
thistle (Silybum marianum) extract (silymarin) [11]. This
compound possess anti-inflammatory and antioxidative ef-
fects [12]. It has also been reported that silymarin has pro-
tective effects against ethanol-induced brain injury [13],
and neurotoxicity induced by lipopolysaccharide (LPS)
[14]. In this study, we investigated the effect of silymarin
on the memory impairment induced by Aβ1-42 injection
in rats. We also examined its effect on changes in APP
gene expression in the rats’ brain.Materials and methods
Animals
Male Wistar rats weighing 250 ±300 g were housed at six
per cage (42 × 26 cm), 23 ± 0.5°C, under a 12/12-h light/
dark cycle (lights on from 8:00 AM to 8:00 PM). Animals
had free access to standard pellet food and water. Behav-
ioral experiments were carried out in a sound-attenuated
room, to which the rats were habituated for at least 1
hour. All experiments were performed in accordance with
to the international guidelines set out in the Guide for
the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996) and approved by the
Research and Ethics Committee of Science and Research
Branch, Azad University.Inducing Alzheimer’s disease in animals and used
compound
Aβ1-42 (Sigma, St Louis, MO, USA), was dissolved in
PBS and incubated at 37°C for 7 days, after which bilat-
eral surgery and injection of Aβ1-42 peptide was done in
rats hippocampus with the help of a stereotaxic appar-
atus (SR-6 N Narishig, Japan) [15]. Ketamine and xylazin
(Alfasan,Woerden-Holland) were used to anesthetize the
rats. Injection was performed slowly into the CA1 region
of the hippocampus at both sides of the brain as men-
tioned in the Paxinos atlas [16].
Silymarin tablets, containing ethyl acetate extracted
Silymarin, were purchased from Goldaru Pharmaceutical
Laboratory, (Isfahan, Iran) and suspended in a distilled
water solution. Treatment group was administered two
different dosages of the compound (70 and 140 mg/kg/
day P.O.) for 4 weeks after the injection with Aβ1–42. A
volume of 0.1 ml/10 g body weight was used.
Animals were divided into four groups with n = 6: the
control group did not undergo surgery, the sham group
underwent surgery (AD inducing) and ws given distilled
water 7 days after surgery, the experimental groups Exp1
and Exp2 received 70 and 140 mg/kg/day of the com-
pound respectively (7 days after surgery).Testing the treatment efficacy
a. Passive avoidance test
A shuttle-cage consisting of two compartments of
equal size (26 × 26 cm) separated by a sliding door
(8 × 8 cm) was used. The shock compartment was
dark in contrast to the starting compartment. Each
experiment started with a pre-training trial, where
the rat was placed in the starting compartment for 5
seconds, after which the sliding door was raised, and
the rat was allowed to stay in the dark compartment
for 10 seconds. The rat was then put back in its cage
and stayed there for 30 minutes after which it was
again put into the shuttle box, and this time, after
entering the dark compartment, a footshock (50 Hz,
1 mA, and 5 s) was delivered. The rat was then put
back into cage and stayed there for 120 seconds.
When put back in the shuttle box, if a latency (in
the order of 120 seconds) is observed before entering
the dark compartment, successful acquisition of
passive avoidance is recorded. A similar procedure
was used 24 hours after training sessions to make a
retention test for evaluating long-term memory.
Higher or lower latencies are taken as indicative of
increase or decrease in memory retention [17].
b. Histological studies of brain tissue
At the end of experiment animals were decapitated
under anesthesia and their brain removed for
histological assessments. First, the brains were fixed
in 10% formalin and later processed for embedding
with paraffin, after which serial sections in 6 mm of
thickness were prepared. For staining of
hippocampus cells, Thioflavin-S method which is
detected by fluorescent microscopy was used [18].
c. Assessing amyloid precursor protein (APP)
expression
Semi-quantitative RT-PCR was performed to assess APP
expression. RNA was extracted from the homogenized
brain tissue of the rats by use of RNX plus kit
(CinnaGen, Iran). Isolated RNA was reverse-transcribed
using the following gene-specific primers: 5′-GGA
TGC GGA GTT CGG ACA TG −3′ (forward) and
5′-GTT CTG CAT CTG CTC AAA G −3′(reverse).
GAPDH was used as housekeeping gene as a control
[5′- GACATGCCGCCTGGAGAAAC −3 ' (forward)
and 5′- AGCCCAGGATGCCCTTTAGT −3′ (reverse)].
The difference in threshold cycles between APP gene
and GAPDH gives the standardized expression level.
PCR were performed using the One-Step SYBR
PrimeScript RT-PCR kit (Cinagen,Tehran-Iran). The
reaction profile consisted of a first round at 95°C for
3 min and then 40 cycles of denaturation at 95°C for
30 s, annealing at 57°C for 30 s, and extension at 72°C
for30 s, with a final extension reaction carried out at
Fig
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loaded onto agarose gels and the resulting bands
from electrophoresis were photographed with a
UV transillumnator.Statistical analyses
The results are expressed as the mean ± S.E.M. Statistical
significance was determined with the one-way ANOVA
followed by Tukey’s multiple comparisons test. A Pearsonure 1 The mean latency to enter the dark chamber on the training
ted with 70 mg/kg Silymarinan and 2Exp group had received 140mg/kcorrelation analysis was performed to elucidate the rela-




Both experimental groups showed significantly longer step-
through latency compared to control group (p < 0.05) both
in the training (Figure 1A) and test (Figure 1B) days.(A) and test day (B). *** is indicative of (P < 0.001). 1Exp group was
g Silymarin.
Figure 3 RT-PCR results comparing gene expression of control,
sham and experimental groups. The locations of the
housekeeping gene and APP are indicated by arrows.
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which had received a higher dose of silymarin showed
slightly lower results in comparison with the 1Exp group.
The 1Exp group has no significant difference in the step-
through latency compared with the control group.
Histological studies of brain tissue
ThT staining was used to show the formation of plaques
in the abeta-treated brain tissues. Usually, amyloid plaques
could be detected in different areas of the brain, including
the hippocampus and cortex (for an example of whole brain
sections showing plaques distribution see Figure three A,B
in reference # [19]). In the present study, both these areas
were observed separately with regard to plaques concen-
tration. The normal hippocampus and cortex tissues are
showed in Figure 2A. Upon injection of abeta, plaques are
formed in both tissues and observed as lighter areas (Figure 2B
and C showing the cortex and hippocampus respectively).
Treatment with silymarin is effective in diminishing the
plaques amount, but here too, administration of 70 mg/Kg
of the compound (Figure 2D and E) has a better effect than
the higher used dose of 140 mg/Kg (Figure 2F and G).
Amyloid precursor protein (APP) expression
Results of electrophoresis are shown in Figure 3. When
the housekeeping gene GAPDH is seen in all samples,Figure 2 Brain slices from the frontal cortex &hippocampus with a m
indicate positions where abeta plaques accumulation has occured, (D,E) 1E
group which was treated with 140mg/kg silymarin. B,D, and E correspondAPP expression is detected in the sham group, which
had only received the compound solvent, and is absent
in both experimental groups.
Discussion
From the different theories that try to explain AD path-
ology, two have been more focused on: the cholinergic
theory, which points to the decrease of acetyl choline as
the main cause of the disease [20,21] and the amyloid
hypothesis, which considers the aggregation of different
derivatives of APP as having an important role in the
pathophysiology of AD [22]. Therapeutic approaches mayagnification of 40. (A), control group, (B,C), sham group: arrows
x group which was treated with 70 mg/kg silymarin and (F,G) 2Ex
to the cortex whereas C,E, and G correspond to the hippocampus.
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as well as efforts toward finding Aβ aggregation blockers
[24], or compounds that would inhibit secretases, i.e. en-
zymes which cleave APP to Aβ peptides of various length
[25]. Some researchers have also tried to employ two or
more therapeutic approaches simultaneously, or to find
molecules that could affect more than one therapeutic
target [26].
Abeta deposits are directly associated with AD. Vari-
ous isoforms of abeta are derived from the precursor
APP, including Aβ25–35 which is one of the most toxic
species detected in the brain of AD patients [27,28]. At
any rate, administration of abeta variants has led to cog-
nitive impairement [9,29,30] which has also been ob-
served in the present study. The hippocampus is known
to be the part of the brain which is first affected by AD
[31] and the result of this damage shows itself by cogni-
tive impairement [32] that has been assessed here by the
shuttle-box test.
Silymarin, the extract of Silybum marianum that con-
tains flavonolignans, has been shown to possess multiple
therapeutic properties, including protective effect against
nerve damage and brain aging [33,34]. This extract may
act via its antioxidant which could protect cells from
oxidative stress damage [33], as it has been shown that
silymarin effect against oxidative stress may be the result
of an increase in reduced glutathione, ascorbic acid and
superoxide dismutase levels [35]. Silymarin had also a
neuroprotective effect in diabetic mice brains [36], and
in mice treated with the brain damaging drug metam-
phetamine [37]. Previous studies have also reported the
beneficial effect of silymarin on Aβ plaques formation,
and the effect was suggested to be related to microglial
inflammation reduction and direct effect on Aβ accumu-
lation by blocking its aggregation in an Alzheimer’s dis-
ease model of transgenic mice [19].
As a matter of fact, silibinin has the ability to inhibit the
amyloid structure formation of various model or patho-
genic proteins in vitro, including Aβ1-42 [38] human
islet amyloid polypeptide [39], and human insulin and
albumin [40]. This may be suggestive of a generic anti-
amyloidogenic effect for this compound, as it has been sug-
gested/observed for various other aromatic/polyphenolic
molecules [41,42]. It should be pointed out that in the
present study, what has been observed is a disaggregative
effect of silymarin on Aβ plaques, since the decrease of
plaques was observed after they had been formed. This is
an important fact, which is directly suggestive of a potential
therapeutic effect for the compounds that are able to
act on existing fibrils. The current view in the search
for AD therapeutic compounds is preferably directed
toward compounds that could preserve the native con-
formation of peptides that may form amyloid structure
[43] or to focus on compounds that inhibit the formationof intermediate structures in the course of amyloid forma-
tion [44,45]. However, it could make sense to include the
compounds that have destabilizing effect on pre-formed fi-
brils into the spectra of potential AD therapies.
Flavonoids are able to cross the blood brain barrier [46],
a fact that should also be true about silymarin, given its
established neuroprotective effect [47]. Furthermore, this
extract presents few side effects and drug interactions [48]
which makes it a quite interesting potential drug for AD.
Silymarin is already used as adjuvant therapy in liver insuf-
ficiency [49], which is another positive point for a poten-
tial drug candidate.
The beneficial effect of silymarin on the short term
memory of rats is thus related with less abeta plaques, but
also, as demonstrated in the present study, with a negative
regulatory effect on the APP gene expression. Increased
expression of APP has been detected in the ageing brain
[50], and specifically related to AD pathophysiology [51].
Furthermore, the overexpression of APP that is present in
the established transgenic mouse model of AD is definitely
linked to the pathological characteristics of the model [52].
As far as we know, this should be a first report about
the extract effect on APP, which is expanding our know-
ledge about the mechanism of action of silibinin in at-
tenuating AD symptoms.
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